Sjogren's Syndrome: Can Ultrasound Be the Key to Earlier Diagnosis?
"New research highlights the potential of salivary gland ultrasounds in improving the accuracy and speed of diagnosing primary Sjogren's syndrome, offering hope for earlier intervention."
Primary Sjogren's syndrome (pSS) presents a significant diagnostic challenge. This autoimmune condition, characterized by dryness of the eyes and mouth, often goes undetected for years, leading to delayed treatment and increased suffering. Traditional diagnostic methods can be invasive or lack sensitivity, underscoring the urgent need for more reliable and accessible tools.
Recent research has focused on the potential of salivary gland ultrasonography (US-SG) as a non-invasive and readily available method for detecting abnormalities associated with pSS. Ultrasound offers a promising alternative for visualizing the salivary glands and identifying telltale signs of the disease.
This article delves into the findings of a study that defines specific US-SG abnormalities indicative of pSS and assesses the reliability of ultrasound as a diagnostic tool. By exploring these advancements, we aim to shed light on how ultrasound could revolutionize the diagnosis and management of Sjogren's syndrome.
Ultrasound’s Growing Role
Salivary gland ultrasound is increasingly used in primary Sjögren’s syndrome because it is widely available, repeatable, non-invasive, and safe. The OMERACT working group standardized SGUS assessment with a 0–3 score, and multiple sources identify ultrasound as the imaging modality of choice for evaluating salivary gland parenchyma. In one 2021 study, 227 patients were enrolled, including 161 with primary Sjögren’s syndrome and 66 non-pSS participants, with evaluation using grayscale ultrasonography, color Doppler sonography, and contrast-enhanced ultrasound.
Diagnosis Remains Multimodal
Sjögren’s syndrome diagnosis generally relies on a combination of clinical assessment and objective testing rather than on ultrasound alone. Commonly used evaluations may include antibody testing, assessment of tear and saliva production, and tissue examination when indicated. Because symptoms and test results can vary, ultrasound is best viewed as a potentially useful complement to established methods, with its interpretation depending on clinical context and practitioner experience.
From Emerging Tool to Clinical Candidate
Ultrasound has emerged as an imaging technique of growing interest in rheumatology, particularly for evaluating the salivary glands in primary Sjögren’s syndrome. A 2020 review described its usefulness in this setting, while a 2022 imaging chapter compared ultrasound and MRI for diagnosis, prognostication, and monitoring. That chapter also examined whether these techniques were sufficiently validated for routine clinical use, reflecting the field’s transition from promising application to formal clinical evaluation.
Unveiling Ultrasound's Potential: Core Indicators of Sjogren's Syndrome
A collaborative study involving international experts sought to establish clear criteria for identifying pSS through US-SG. The researchers focused on defining specific echostructural abnormalities within the salivary glands that could serve as reliable indicators of the disease. These included:
- Consensus Meetings: Experts in SG US imaging convened to select and define key echostructural abnormalities.
- Atlas Development: A preliminary atlas of these defined abnormalities was created to serve as a visual reference.
- Reliability Assessment: The reliability of detecting these abnormalities was tested using both static US-SG images and real-time acquisition in pSS patients.
New Imaging Directions
Recent research is expanding ultrasound assessment beyond the salivary glands. An April 13, 2026 study investigated lacrimal gland color Doppler ultrasonography because primary Sjögren’s syndrome may involve the lacrimal glands earlier and more frequently. A 2025 review reported that salivary gland ultrasonography is increasingly used in suspected Sjögren’s disease and described SGUS as a first-line, non-invasive, non-irradiating, and low-cost imaging modality.
Ultrasound Is Not a Standalone Answer
The available material does not establish that ultrasound can replace the full diagnostic process. One source describes Sjögren’s diagnosis as based on five objective tests, including histology, immunology, two ophthalmologic tests, and salivary-flow evaluation. Although another guide presents SGUS as a non-invasive, high-precision approach and contrasts it with biopsy, the broader challenge remains identifying the right imaging tool for diagnosis, follow-up, and prognosis.
Ultrasound Versus Biopsy
Salivary gland ultrasound and lip biopsy answer different clinical needs and involve different trade-offs. The cited patient guides specifically compare the risks of lip biopsy with salivary ultrasound and discuss whether SGUS can replace biopsy. They also place both tests alongside Schirmer’s testing and saliva-based evaluation, indicating that test selection is part of a broader diagnostic assessment rather than a universal one-test decision.
A Brighter Future for Sjogren's Syndrome Diagnosis
This research offers a significant step forward in improving the diagnosis of primary Sjogren's syndrome. By identifying reliable ultrasound markers and establishing a preliminary atlas, the study provides a foundation for more consistent and accurate diagnoses.
Promising Evidence, Careful Interpretation
A systematic review examined the diagnostic accuracy of salivary gland ultrasound in adults with sicca symptoms being investigated for primary Sjögren’s syndrome. The included diagnostic and validation studies used recognized diagnostic criteria and assessed SGUS as part of that investigation. This supports ultrasound as a serious diagnostic candidate, while the review design also underscores the importance of validation and standardized interpretation before treating it as definitive on its own.
Expanding the Imaging Toolbox
Future research may clarify how ultrasound can support earlier detection and longitudinal monitoring of Sjögren’s syndrome. Potential directions include refining standardized scoring, evaluating additional glandular targets, and determining how imaging should be combined with laboratory, eye, saliva, and tissue findings. These possibilities remain research priorities rather than established clinical conclusions.
Standardization and Access
The broader challenge is integrating a useful, accessible imaging technique into a diagnosis that already depends on multiple objective assessments. Differences in equipment, operator skill, scoring, and clinical pathways may affect how consistently ultrasound findings are applied. Broader adoption will therefore require continued validation, standardization, and clear guidance on how imaging fits with existing tests.
A Practical, Patient-Friendly Tool
Salivary gland ultrasound is described as widely available, repeatable, non-invasive, and safe for patients undergoing evaluation or follow-up for primary Sjögren’s syndrome. Those characteristics may make repeated structural assessment more practical than approaches that are more invasive or difficult to repeat. Its value in real-world care is therefore tied not only to diagnostic information, but also to how comfortably and consistently patients can undergo monitoring.
The findings suggest that trained experts can use ultrasound to identify key indicators of pSS, potentially leading to earlier intervention and improved patient outcomes. The non-invasive nature of ultrasound also makes it a more accessible and patient-friendly diagnostic option.
Further research is needed to validate these findings in larger populations and to explore the potential of ultrasound in monitoring disease progression and treatment response. However, this study provides compelling evidence that ultrasound holds great promise as a valuable tool in the fight against Sjogren's syndrome.